Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 12/20 | 0.37 |
| ▸ | CCND1 | P24385 | 12/20 | 0.37 |
| ▸ | CCND2 | P30279 | 12/20 | 0.37 |
| ▸ | CCND3 | P30281 | 12/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | BMI1 | P35226 | 4/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800393 | 1.00 | CDK4 (0.37) | CDK4CCND1CCND2CCND3GRM5 | |
| SCHEMBL14800247 | 0.88 | P2RX3 (0.37) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL14800249 | 0.88 | P2RX3 (0.37) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL14800991 | 0.85 | GRM5 (0.39) | CDK4CCND1CCND2CCND3GRM5 | |
| SCHEMBL14816286 | 0.79 | PDE4B (0.31) | — | |
| SCHEMBL14816285 | 0.79 | PDE4B (0.31) | — | |
| SCHEMBL14800491 | 0.76 | P2RX3 (0.40) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL14818895 | 0.74 | TNIK (0.40) | GRM5 | |
| SCHEMBL14837781 | 0.73 | P2RX3 (0.33) | — | |
| SCHEMBL14800966 | 0.72 | NPC1 (0.40) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CDK4 3036/4885CCND1 4177/4885CCND2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.